Xellia Pharmaceuticals is a specialty pharmaceutical company that provides anti-infective treatments and other critical care therapies for serious and often life-threatening conditions. The company manufactures and supplies Active Pharmaceutical Ingredients to pharmaceutical companies.

Xellia Pharmaceuticals

Ferring Pharmaceuticals focuses on developing innovative treatments in reproductive medicine and maternal health, as well as in gastroenterology and urology.

Ferring Pharmaceuticals

LEO Pharma is dedicated to medical dermatology, focusing on advancing the science of dermatology through research and development.

LEO Pharma

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.

Metric
Company Name	Xellia Pharmaceuticals	Ferring Pharmaceuticals	LEO Pharma	H. Lundbeck A/S
Symbol				LUN
MSH ID	COM:XELLIA	COM:FERRING	COM:LEO-PHARMA	COM:LUNDBECK
Market	PRIVATE	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services	Healthcare
Industry	Pharmaceuticals	Pharmaceuticals	Pharmaceuticals	Drug Manufacturers - Specialty & Generic
Country	DK	CH	DK	DK
Stage
Employee Count				5.35K
Website	xellia.com	ferring.com	leo-pharma.com	lundbeck.com
LinkedIn
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue				2.82B
Revenue (LTM)
Revenue (NTM)
Gross Profit				2.18B
EBITDA				720.26M
Operating Income				452.47M
Net Income				324.30M
EPS				0.33
Diluted EPS				0.33
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin				0.78
Operating Profit Margin				0.17
EBITDA Margin				0.26
Net Profit Margin				0.12
Return on Equity				0.11
Return on Assets				0.07
Return on Capital Employed				0.11

COM:XELLIA

Xellia Pharmaceuticals

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio				26.03
P/B Ratio				1.88
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio				1.89
EV Multiple				9.97

Metric
Days Sales Outstanding
Days Payables Outstanding				391.61
Days Inventory Outstanding				368.68
Operating Cycle				448.16
Cash Conversion Cycle				101.40
Asset Turnover				0.53

Metric
Operating Cash Flow				577.80M
Free Cash Flow				506.85M
Cash Flow to Debt				1.23
Operating Cash Flow/Sales				0.23
Free Cash Flow Yield

Metric
Cash & Equivalents				709.50M
Accounts Receivable				-23.65M
Inventory				626.94M
Goodwill				779.88M
Debt to Capitalization				0.23
Debt to Assets				0.15
Current Ratio				0.98
Quick Ratio				1.32

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue				0.23
SG&A to Revenue				0.06